Special Issue

Novel Vaccines for Porcine Viruses

Message from the Guest Editors

Intensive pig farming can lead to outbreaks of viral diseases, which is a critical concern for animal welfare, the economy, food security, and an increase in the use of antibiotics. Vaccination has been proven to be the most effective measure for disease control. Commercial vaccines are currently available to control porcine viruses such as circovirus, porcine epidemic diarrhoea virus (PEDV), parvovirus, swine influenza virus (SIV), porcine reproductive and respiratory syndrome virus (PRRSV), and foot-and-mouth disease virus. Several vaccine technologies and platforms can be used to construct novel vaccines against viral diseases of pigs. These technologies include inactivated (killed) and modified live vaccines, virus-like particles and subunit vaccines, synthetic peptides, nanoparticles, viral-vectored (vector-based) vaccines, nucleic acids (DNA and mRNA), and bacterial vectored vaccines. In this Special Issue of *Viruses*, we invite research and review papers that contribute to the development of novel vaccines for porcine viruses.

Guest Editors

Prof. Dr. Levon Abrahamyan

Swine and Poultry Infectious Diseases Research Center (CRIPA), Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC J2S 2M2, Canada

Dr. Alexander Zakhartchouk

Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada

Deadline for manuscript submissions

closed (28 February 2025)

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/178992

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/viruses

About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed
HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).